Research programme: cancer therapeutics - Oasmia

Drug Profile

Research programme: cancer therapeutics - Oasmia

Alternative Names: Anticancer bio-regulators - Oasmia; Carbomexx; Carboplatin - Oasmia; OAS-19

Latest Information Update: 21 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oasmia Pharmaceutical
  • Class Platinum complexes; Small molecules; Taxanes
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA intercalators; DNA synthesis inhibitors; Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 20 Nov 2015 Phase III development is ongoing Sweden
  • 30 Dec 2010 Development is ongoing in Sweden
  • 28 Jul 2006 Preclinical trials in Cancer in Sweden (parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top